Harbin Pharmaceutical Group Co Ltd banner

Harbin Pharmaceutical Group Co Ltd
SSE:600664

Watchlist Manager
Harbin Pharmaceutical Group Co Ltd Logo
Harbin Pharmaceutical Group Co Ltd
SSE:600664
Watchlist
Price: 3.69 CNY 0.54%
Market Cap: ¥9.3B

P/OCF

33.2
Current
118%
More Expensive
vs 3-y average of 15.2

Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.

P/OCF
33.2
=
Market Cap
¥10.5B
/
Operating Cash Flow
¥280.1m

Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.

P/OCF
33.2
=
Market Cap
¥10.5B
/
Operating Cash Flow
¥280.1m

Valuation Scenarios

Harbin Pharmaceutical Group Co Ltd is trading above its 3-year average

If P/OCF returns to its 3-Year Average (15.2), the stock would be worth ¥1.69 (54% downside from current price).

Statistics
Positive Scenarios
0/4
Maximum Downside
-60%
Maximum Upside
No Upside Scenarios
Average Downside
46%
Scenario P/OCF Value Implied Price Upside/Downside
Current Multiple 33.2 ¥3.69
0%
3-Year Average 15.2 ¥1.69
-54%
5-Year Average 13.1 ¥1.46
-60%
Industry Average 25 ¥2.78
-25%
Country Average 18.3 ¥2.03
-45%

Forward P/OCF
Today’s price vs future operating cash flow

Not enough data available to calculate forward P/OCF

Peer Comparison

All Multiples
P/OCF
P/E
All Countries
Close
Market Cap P/OCF P/E
CN
Harbin Pharmaceutical Group Co Ltd
SSE:600664
9.3B CNY 33.2 20.7
US
Eli Lilly and Co
NYSE:LLY
825.8B USD 49.1 40
US
Johnson & Johnson
NYSE:JNJ
548.5B USD 22.4 26.1
CH
Roche Holding AG
SIX:ROG
248.4B CHF 13.7 20.1
UK
AstraZeneca PLC
LSE:AZN
215.6B GBP 19.6 27.9
CH
Novartis AG
SIX:NOVN
218.9B CHF 14.3 19.6
US
Merck & Co Inc
NYSE:MRK
272.3B USD 16.5 14.9
IE
Endo International PLC
LSE:0Y5F
244.4B USD 907.7 -83.6
DK
Novo Nordisk A/S
CSE:NOVO B
1.2T DKK 9.9 11.5
US
Pfizer Inc
NYSE:PFE
150.6B USD 12.9 19.4
US
Bristol-Myers Squibb Co
NYSE:BMY
117.3B USD 8.3 16.6
P/E Multiple
Earnings Growth PEG
CN
Harbin Pharmaceutical Group Co Ltd
SSE:600664
Average P/E: 21.7
20.7
11%
1.9
US
Eli Lilly and Co
NYSE:LLY
40
32%
1.3
US
Johnson & Johnson
NYSE:JNJ
26.1
8%
3.3
CH
Roche Holding AG
SIX:ROG
20.1
14%
1.4
UK
AstraZeneca PLC
LSE:AZN
27.9
25%
1.1
CH
Novartis AG
SIX:NOVN
19.6
14%
1.4
US
Merck & Co Inc
NYSE:MRK
14.9
14%
1.1
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -83.6 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
11.5
0%
N/A
US
Pfizer Inc
NYSE:PFE
19.4
22%
0.9
US
Bristol-Myers Squibb Co
NYSE:BMY
16.6
16%
1

Market Distribution

In line with most companies in China
Percentile
67th
Based on 6 232 companies
67th percentile
33.2
Low
0.2 — 9.8
Typical Range
9.8 — 36.5
High
36.5 —
Distribution Statistics
China
Min 0.2
30th Percentile 9.8
Median 18.3
70th Percentile 36.5
Max 266 666.7

Harbin Pharmaceutical Group Co Ltd
Glance View

Market Cap
9.3B CNY
Industry
Pharmaceuticals

Founded amidst the industrial boom of the 1950s, Harbin Pharmaceutical Group Co., Ltd. has evolved into one of China's pharmaceutical giants, headquartered in Harbin, Heilongjiang Province. Historically grounded in traditional Chinese medicine, it has grown into a multifaceted enterprise that blends its cultural heritage with modern pharmaceutical science. Harbin Pharma's journey from its humble beginnings to becoming a household name is marked by its robust research and development efforts, which are key to its operations. The company's vertical integration strategy stretches through the entire pharmaceutical value chain, encompassing research, production, and distribution, thereby optimizing efficiency and maintaining quality control across its vast product lines. This structure not only helps minimize costs but also allows Harbin Pharma to quickly adapt to changes in the healthcare market. The company primarily generates revenue through the production and sale of both prescription and over-the-counter drugs, catering to a diverse array of health needs globally. A significant portion of its income stems from the manufacture of antibiotics, patent drugs, and biological products, though it also maintains a strong presence in the consumer health sector with vitamins and dietary supplements. Strategically, Harbin Pharma leverages its extensive distribution network, one of the largest in China, ensuring that its products reach even the most remote areas. Moreover, the company benefits from partnerships and collaborations with international pharmaceutical companies, which allow it to expand its global footprint and enhance its product offerings. In essence, Harbin Pharmaceutical Group's success is anchored in its adaptive business strategies, commitment to innovation, and ability to navigate the complexities of the rapidly evolving pharmaceutical landscape.

Intrinsic Value
5.94 CNY
Undervaluation 38%
Intrinsic Value
Price ¥3.69
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett